JUXTAPID: payments to doctors
Payments that named JUXTAPID as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $21.5M
- Providers
- 1,667
- Transactions
- 2,414
- Average per transaction
- $8,893
The per-transaction average — $8,893 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,667 providers the average total is $12,878, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Amryt Pharma Holdings Ltd | $8,105,644 | 37.8% |
| Aegerion Pharmaceuticals, Inc. | $7,713,998 | 35.9% |
| Chiesi USA, Inc. | $5,648,188 | 26.3% |